This paper focuses on the identification of the key determinants of the interstate differences in the incidence of COVID-19. It finds that it is best to have a dynamic, transparent, and explicit formula for the interstate allocation of vaccines under conditions of deficient supply. This is ideally handled by an objective expert body.
